Ovarian survival after pelvic radiation: transposition until the age of 35years by Hoekman, E.J. et al.
Vol.:(0123456789) 
Archives of Gynecology and Obstetrics (2018) 298:1001–1007 
https://doi.org/10.1007/s00404-018-4883-5
GYNECOLOGIC ENDOCRINOLOGY AND REPRODUCTIVE MEDICINE
Ovarian survival after pelvic radiation: transposition until the age 
of 35 years
Ellen J. Hoekman1  · Dan Knoester1 · Alexander A. W. Peters1 · Frank W. Jansen1 · Cornelis D. de Kroon1 · 
Carina G. J. M. Hilders2
Received: 7 March 2018 / Accepted: 22 August 2018 / Published online: 14 September 2018 
© The Author(s) 2018
Abstract
Purpose To evaluate the effectiveness of ovarian transposition (OT) prior to radiation therapy (RT) and to evaluate the effect 
of age on ovarian survival (OS) after OT.
Methods We performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radia-
tion, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All 
women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25–30; 31–35 
and 36–40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement 
therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. 
Women were censored at recurrence.
Results Twenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0–63.0 Gy) 
and 46.3 Gy (45.0–50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% 
CI 3.48–11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25–30, 30–35 
and 35–40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and 
p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation 
significantly altered ovarian survival.
Conclusions Our data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years 
and needs to be discussed in patients aged 36–40 years.
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Introduction
Premature ovarian insufficiency (POI) after high gonado-
toxic therapy is one of the side effects of cancer treatment 
with high impact on quality of life. Due to the continued 
refinements in treatment regimens, the rates of complete 
remission and cure have been improved. Thereby, quality 
of life after cancer is becoming a very important issue in a 
large number of women [1]. For example in the Netherlands, 
around 350 new cases of fertile patients are diagnosed with 
cervical cancer every year [2]. Furthermore besides cervi-
cal cancer, patients with Hodgkin’s disease, rectal cancer 
and other malignancies who need pelvic irradiation are at 
high risk where a small dose of irradiation can already cause 
infertility and POI [3, 4].
Infertility, climacteric symptoms such as vasomotor hot 
flashes, urogenital and sexual dysfunction and emotional 
disturbances are the side effects of POI with high impact 
on quality of life [5, 6]. Especially, estrogen withdrawal in 
young women is associated with decreased bone mineral 
density and impaired lipid profile with increased risk of 
ischemic heart disease [7, 8]. Although hormone replace-
ment therapy is highly effective in counteracting these risks, 
long-term studies equating endogenous and exogenous 
estrogens are lacking [9]. Moreover, hormone replacement 
therapy (HRT) in women with POI may raise certain seri-
ous adverse side effects [10]. Finally, the success of this 
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therapy depends largely on the patient’s compliance of the 
prescribed protocol [11]. As it has been shown, a small num-
ber of women follow their HRT regularly [12].
In an attempt to protect the ovaries from pelvic irradia-
tion and prevent POI, ovaries can be transposed outside the 
radiation field, also known as ovarian transposition (OT). 
This surgical technique has been performed since 1952, 
with varying rates of success [13]. The last 30 years, POI 
after transposition ranges from 33 to 100%, using various 
techniques and modes of follow-up [14–28]. One reason of 
ovarian failure after OT may be the influence of scattered 
radiation therapy [29]. Moreover, it has been postulated that 
decreased blood flow to the ovaries, due to bending of the 
vessels as a result of the transposition, damage during sur-
gery or as a side effect of the radiation therapy, increases the 
risk of POI. With regard to side effects of OT, the incidence 
of symptomatic ovarian cysts after OT is reported to range 
between 0 and 34% [15, 19, 22, 27]. In some of the reported 
cases, removal of the transposed ovary was necessary. More 
disturbingly, several studies have reported ovarian metasta-
ses in transposed ovaries [30, 31]. Thus, whether transposing 
the ovaries prior to radiation is a safe and effective procedure 
remains an ongoing issue.
We conducted a retrospective case–control study to evalu-
ate the effectiveness and complications of ovarian transposi-
tions prior to radiation therapy. Moreover, we evaluated the 
effect of age on ovarian survival after ovarian transposition.
Materials and methods
From hospital databases of the Leiden University Medical 
Center, all patients were selected in whom ovarian transposi-
tion was performed between 1988 and 2010. From the same 
databases in which data were entered prospectively, women 
eligible for the control group were selected: pre-menopausal 
cervical cancer patients in whom the ovaries were not trans-
posed prior to pelvic radiation.
Data collection
Medical records of both cases and controls were reviewed 
for cancer treatment, survival, relapse and adjuvant cancer 
treatment. Since our study is retrospective by design, there 
was no obligation to have the protocol approved by our insti-
tutional review board.
With regard to ovarian survival, climacteric symptoms 
(irregular or no bleeding pattern, hot flushes), the use of 
hormonal replacement therapy and laboratory values (FSH 
and estradiol) were evaluated whenever available. Finally, 
complications of OT were assessed. Ovarian survival was 
defined as the absence of ovarian failure. Ovarian insuffi-
ciency was defined as follows: whenever at least two of the 
following criteria were reported, women were considered 
to suffer from ovarian failure: (1) climacteric symptoms, 
(2) use of hormonal substitution, (3) menopausal laboratory 
value (i.c. FSH > 40 IU/mL and/or estradiol < 100 pmol/L). 
Patients with normal ovarian function were censored at the 
date of the last follow-up with explicit data on the above-
mentioned criteria for ovarian survival or at the date of 
systemic high gonadotoxic treatment for recurrence or 
metastatic disease. Follow-up of the ovarian function was 
continued until the first date of POI or in case of ovarian sur-
vival until a maximum of 5 years (when possible). Follow-up 
was reviewed until January 2018.
Statistical analysis
The collected data was analyzed using SPPS  20® (SPSS Inc, 
Chicago, IL, USA). Patient characteristics were compared 
with an independent T test. Overall ovarian survival was 
estimated by the Kaplan–Meier method, and the log-rank 
test was used to compare ovarian survival between cases 
and controls, the influence of age, additional chemotherapy 
and/or intra-vaginal radiation therapy. The Mann–Whitney 
U was performed to detect the difference of time until POI 
between OT and controls. With regard to age, the effect of 
RT after OT on ovarian survival was estimated for three 
different groups of age: 25–30  years, 31–35  years and 
36–40 years. Figures were generated by Prism GraphPad 5 
(GraphPad Software Inc., La Jolla, CA, USA).
Results
The follow-up of 27 patients who underwent OT prior to 
pelvic radiation were reviewed (OT group). The majority 
of patients suffered from cervical squamous cell carcinoma. 
Other patients suffered from rectal adenocarcinoma (n = 3, 
stage 2, 3 and 3) or schwannoma (n = 1, grade II). Twenty-
nine patients who suffered from cervical carcinoma and 
treated with pelvic radiation therapy (7 patients with ade-
nocarcinoma, 22 patients with squamous cell carcinoma) in 
whom OT was not performed were included in the control 
group. In all women except one case (concomitant chemo-
therapy and pelvic radiation), surgery was the primary ther-
apy. Characteristics, including details on adjuvant radiation 
therapy and concomitant chemotherapy of both cases and 
controls, are shown in Table 1.
In most patients, standard follow-up treatment was per-
formed according to the Dutch national guidelines for cancer 
treatment. The follow-up, for example of cervical cancer 
patients consists of a 3-month interval in the first 2 years, 
6-month interval at year 3 and 4 and a 1-year interval at year 
5. Patients were seen earlier on request or when there were 
complaints.
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Surgical procedure of OT
Ovarian transposition was performed during laparotomy 
(n = 18, 66.7%) for primary cancer treatment or by lapa-
roscopy scheduled especially for OT (n = 9, 33.3%). In all 
surgical reports, the normal appearance of the ovaries was 
mentioned. The proprial ligament and fallopian tube were 
ligated and the ovarian vascularity in the infundibulopel-
vic ligament was dissected upward to allow transposition 
of the ovary to the upper abdomen above the level of the 
umbilicus. The ovary, along with the attached fallopian tube, 
was attached to the fascia of the anterior abdominal wall 
with a non-absorbable suture. No additional measurements 
were performed to reduce the risk of ovarian torsion. In 21 
patients, the right ovary was transposed, while the left ovary 
was transposed in four patients and in two other patients both 
ovaries were transposed. In one patient, data about the trans-
position site were not known. The decision of transposing 
one ovary instead of two was due to uncertainty of additional 
risks such as the formation of cysts and torsion at the time.
Additional cancer treatment
All patients received external pelvic radiation therapy with 
a mean dose of 44.8 Gy (range 25–63) in the OT group 
and 46.3 Gy (range 45–50) in the control group (NS). Ten 
patients of the OT group and 17 patients of the control group 
received additional brachytherapy (16.93 versus 13.89 Gy, 
p < 0.05) (Table 1). Nine patients received additional chemo-
therapy, mono or combined therapy of cisplatin, taxol and/
or topotecan, respectively.
Ovarian survival
The mean follow-up of OT patients, from RT until the lat-
est date of normal ovarian function, was 34.5 months (min. 
1.5–96.0).
In three cases, no details on ovarian function could be 
obtained for the medical records. These women were not 
included in the calculation of ovarian survival. One patient 
with cervical cancer did not experience menopausal com-
plaints, despite elevated serum FSH (62 and 75 IU/mL) at 
two different measurements: although she strictly did not 
fulfill the criteria for ovarian failure, she was considered to 
be suffering from ovarian insufficiency from the date of the 
first elevated serum FSH.
Eight (29.6%) women in the OT group suffered from 
ovarian failure 5 years after pelvic radiation. Ovarian sur-
vival at 5 years was 60.3% (OT group) versus 0.0% (con-
trols) (p < 0.001, (p < 0.000 95% CI 3.48–11.50) (Fig. 1). 
Median time to ovarian failure after radiation therapy was 
significantly shorter in the control group, 2.6 months, versus 
cases, 7.49 months (p = 0.009). Four out of the total of eight 
patients in whom OT failed suffered from ovarian failure 
within 6 months after radiation therapy. In two patients, 
the transposed ovaries (both ovarian survival at the time of 
surgery) were removed after, respectively, 2 (due to pseu-
domyxoma peritonei) and 45 months (preventive surgery 
Table 1  Patient characteristics
LN lymph node, NS non-significant
Transposition Control p value
Mean age (years) 33.4 36.67 0.02
 25–30 9 4
 31–35 7 10
 36–40 8 8
 40–44 3 7
Primary cancer
 Cervical cancer 23 29
 Rectal cancer 3 0
 Schwannoma 1 0
FIGO
 1b 15 25
 2a 6 3
 2b 2 1
 Other 4 0
Lymph node status NS
 LN+ 8 12
 LN− 19 17
Post-operative therapy
 Mean external radiation dose 
(Gy)
44.88 46.32 NS
 Mean internal radiation dose (Gy) 16.93 13.89 0.021
 Chemoradiation treatment 9 0
Adnex in situ NS
 1 adnexa 5 3
 2 adnexa 22 26
Disease recurrence 5 5
Diseased 3 5
Fig. 1  5 years ovarian survival, case and controls
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because of MSH-6 mutation). These cases were censored for 
ovarian survival analyses at the date of surgery.
Of the 24 patients in the OT group included in the ovarian 
survival analyses, 10 patients received external and intra-
vaginal radiation therapy. Additional vaginal brachytherapy 
showed no significant difference in ovarian survival versus 
patients who received external radiation therapy alone: 
5 years ovarian survival 58.3 versus 62.3% (p = 0.91, 95% CI 
33.15–52.94, Fig. 2). Within the control group, the addition 
of vaginal brachytherapy did not show a significant differ-
ence in ovarian survival after 5 years either: the median time 
until ovarian failure after OT was 2.4 years without brachy-
therapy (95% CI 0.197–4.54) versus 2.6 years after the addi-
tion of brachytherapy (95% CI 1.24–3.96) (p = 0.501).
Nine patients received chemotherapy, of which two 
patients received chemotherapy after ovarian failure, one 
patient received 80 mg/kg cisplatin and was lost to follow-
up, and another patient received taxol, ifosfamide and cis-
platin and was censored at the start of the chemotherapy. 
The other five patients were included in the ovarian sur-
vival analyses and received concomitant pelvic radiation 
and chemotherapy (four patients received five or six doses 
of cisplatin 40 mg/m2 weekly schedule, and one patient 
received cisplatin 40 mg/m2 and topotecan weekly schedule). 
There was no significant difference in the ovarian survival 
of transposed ovaries receiving chemoradiation or radiation 
therapy alone, although the number of patients was low in 
this analysis (p = 0.41).
There was a non-significant decrease in 5 years ovar-
ian survival after OT with increasing age (p = 0.16, Fig. 3). 
Despite the decrease in ovarian survival after OT with 
increasing age, in all age groups (25–30, 30–35 and 35–40) 
ovarian survival after OT was significantly better compared 
to women without OT (p = 0.001; p = 0.004 and p = 0.000, 
respectively (Fig. 3a–c). Although ovarian survival was 
significantly longer after OT in all the groups, when con-
sidering OT in women aged 35–40 years, we have to con-
sider the small proportion of women aged 35–40 years who 
benefited from OT (two out of eight patients, Table 2).
In three patients, OT was performed at the age of 
42 years: two of these patients were among the three women 
who were lost to follow-up and consequently not included 
in the survival analysis; the other 42-year-old woman had 
normal ovarian function 5 years after OT.
None of the patients had become pregnant during follow-
up, and high technological surrogacy was not performed.
Fig. 2  Ovarian survival after OT with or without intra-vaginal radia-
tion therapy
Fig. 3  5-years ovarian survival after OT for different age groups
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Complications
All nine laparoscopic surgeries specially performed for 
ovarian transposition were uneventful. One ovarian tor-
sion requiring oophorectomy of the transposed ovary (OT 
performed by laparotomy during primary surgery) was 
recorded. However, before oophorectomy, the patient was 
already diagnosed with POI despite OT. In none of the cases 
in this series, ovarian metastases were diagnosed during 
follow-up.
Discussion
Our data show that ovarian transposition (OT) prior to pelvic 
radiation results in a significant increase in ovarian survival 
after pelvic radiation: 5 years ovarian survival 60.3% after 
OT versus 0.0% without OT (p < 0.001) Published rates of 
POI and complications after OT prior to pelvic radiation dif-
fer greatly (ovarian survival between 33% and 100%), which 
results in an ongoing debate about the safety and effective-
ness of the procedure [14–28, 32]. However, most of the 
published data suffer from methodological flaws, since most 
studies are case series and non-comparative. Therefore, the 
results of effectiveness or disadvantages are not conclusive. 
The ovarian survival rates reported in this comparative study 
strongly support the advocates of ovarian transposition given 
its significant increase in ovarian survival after pelvic radia-
tion and low complication rate.
Our results show that additional intra-vaginal radiation 
therapy and/or low dose chemotherapy (as part of chemo-
radiation therapy) has no significant impact on ovarian 
survival. Hence, these women should not be excluded from 
the option of OT. Unfortunately, due to small numbers it 
was not possible to compare patients after OT, receiving 
chemotherapy, EBRT and VBRT (n = 4), versus patients 
receiving EBRT and VBRT (without chemotherapy, n = 4). 
The PORTEC-2 trial showed the efficacy and reduced 
side effects of VBRT compared with external beam pelvic 
radiotherapy (EBRT) for patients with high–intermediate 
risk of endometrial cancer. Additionally, patients receiv-
ing VBRT only reported less bowel symptoms, which pro-
vided a better quality of life than after EBRT, contributing 
to the theory that VBRT delivers less scatter radiation that 
results in less impact on the surrounding tissue [33]. In 
contrast to our findings, Morice et all reported ovarian sur-
vival of 100% after OT, 90% after OT and brachytherapy 
and 60% after OT, brachytherapy and external radiation 
therapy [19]. Furthermore, ovarian survival after OT, 
external radiation therapy and brachytherapy has been 
described, respectively, in 33%; 80% and 100% [34–36]. 
Yamamoto reported a 5 year ovarian survival rate of 38.5% 
after OTs and radiation therapy [16]. Furthermore, Beuk-
ers reported ovarian survival in 41% of patients after OT 
and radiation therapy, with a mean follow-up of 43 months 
[26]. Hence there is no evidence to supports not transpos-
ing ovaries in case of pelvic chemoradiation in combina-
tion with intra-vaginal brachytherapy.
In the literature, the age above 40 years has often been 
used as a cutoff point. In our cohort three women older than 
40 years underwent OT, of whom two were lost to follow-
up. Hence, it is uncertain whether OT of women above 
the age of 40 years is worthwhile. Additionally, the ovar-
ian survival was statistically significant in all age groups 
(Fig. 3), although on having a close look into the age group 
of 35–40 years only two out of eight patients (25%) experi-
enced ovarian survival until 74 months (Table 2).
Previous studies have shown a correlation between age 
and the dose of pelvic radiation and ovarian failure. Ham-
ish et al. described ovarian failure at the age of 10 years 
after exposure to 18.4 Gy, but at the age of 30 years ovar-
ian failure occurred after exposure to 14.3 Gy [4]. The 
effect of OT in women above 40 years of age is limited, 
because of reduced fertilization and a higher risk of pre-
mature ovarian failure despite OT [19]. In addition, pro-
gressively smaller doses of chemotherapy are required to 
produce ovarian failure with increasing age [37–39]. In our 
opinion, to prevent POI, ovarian transposition should be 
Table 2  Patient characteristics 
of patients after ovarian 
transposition and aged 
35–40 years
Nr. Age at RT Ovarian 
survival
Time (months) Treatment Notes
1 35.7 Yes 74.7 ERT None
2 37.6 Yes 23.7 ERT None
3 37.1 Yes 43.8 ERT BSO
4 35.7 No 5.1 ERT 1 ovary in situ
5 35.8 No 10.8 ERT Transposi-
tion of two 
ovaries
6 38.1 No 18.7 ERT BSO
7 38.6 No 3.9 ERT None
8 35.7 No 9.9 ERT and Cisplatin None
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discussed with all patients below the age of 35 years who 
need external radiation to the pelvis.
Despite OT, some women still suffer from ovarian 
failure after pelvic radiation. It has been shown that, due 
to scattered radiation, a substantial loss of ovarian func-
tion might still occur despite OT [21, 24, 40]. Further-
more, POI after OT and radiation therapy can be caused 
by migration of the ovaries back into the small pelvis 
after OT. Williams et al. reported ovarian failure which 
accounted in most patients of ovaries migrating back to 
the radiation area, as observed at repeat surgery [40]. An 
option for detecting the position of the ovaries is to attach 
a radio-opaque marker to the ovaries during transposition. 
The ovaries can be identified by imaging done for radia-
tion planning and allows the radiotherapist to adjust the 
radiation field when necessary. Within our series, not all 
transposed ovaries were clipped by radio-opaque markers. 
Thus, in some cases it is unclear whether the ovary was 
still positioned outside the radiation field or had migrated 
back to the pelvis. In this context, we advise using radio-
opaque markers to visualize the ovaries prior to and during 
radiation therapy. Finally, even in women after OT without 
radiation therapy, POI has been reported in up to 7% of 
women [15, 17, 18, 26]. Thus apart from damage due to 
radiation, multiple factors may contribute to failure of OT 
prior to radiation therapy.
Advocates of OT are supported by the data that POI 
has a high impact on the quality of life and may even 
cause more stress to the particular woman than suffering 
from cancer [25, 26]. Therefore, it is worthwhile to pre-
vent POI and preserve ovarian function and/or fertility. 
However, complications due to OT should be weighted. 
The major adverse events related to OT are, however, rare: 
the occurrence of ovarian cysts, ovarian torsion and ovar-
ian metastases on the transposed ovary [19, 20, 23]. In 
the presented series, adverse events were rare: an ovarian 
torsion was reported in the transposition group and was 
surgically removed. No ovarian metastases were reported 
in this study and surgical procedures were uneventful. In 
our opinion, OT is a safe procedure and should be offered 
to women below 40 years old whenever pelvic radiation 
is indicated.
In conclusion, our data show that ovarian transposition 
prior to pelvic radiation is effective, since both ovarian sur-
vival (p < 0.001) and time to POI (p < 0.01) are significantly 
better after OT prior to radiation therapy. Despite the low 
complication risk of ovarian transposition, we advise only 
ovarian transposition in women until the age of 35 years 
prior to pelvic radiation to prevent POI with its disad-
vantageous impact on the quality of life. In women aged 
35–40 years, OT can be discussed when the procedure is 
executed during primary cancer surgery; however, the 
chances of long-term ovarian survival are limited.
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